학술논문
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial
Document Type
article
Author
Fichtenbaum, Carl J; Ribaudo, Heather J; Leon-Cruz, Jorge; Overton, Edgar T; Zanni, Markella V; Malvestutto, Carlos D; Aberg, Judith A; Kileel, Emma M; Fitch, Kathleen V; Van Schalkwyk, Marije; Kumarasamy, Nagalingeswaran; Martinez, Esteban; Santos, Breno Riegel; Joseph, Yvetot; Lo, Janet; Siminski, Sue; Melbourne, Kathleen; Sponseller, Craig A; Desvigne-Nickens, Patrice; Bloomfield, Gerald S; Currier, Judith S; Hoffmann, Udo; Douglas, Pamela S; Grinspoon, Steven K; Curran, Adrian; Baranauskas, Adrienne; Wilkin, Aimee; Abrams-Downey, Alexandra J; Eckard, Allison Ross; Wurcel, Alysse G; González-Cordón, Ana; Paez, Armando; Sha, Beverly E; Santos, Breno; Yoshida, Carina Beppu; Rolle, Charlotte-Paige; Somboonwit, Charurut; Funk, Connie; Gómez-Ayerbe, Cristina; Frank, Cynthia; Nixon, Daniel E; Skiest, Daniel J; Choi, David; Mushatt, David M; Rial-Crestelo, David; Perez, Deborah K; Burke, Deirdre J; dos Santos, Desirée VG; Jayaweera, Dushyantha T; Gardner, Edward M; DeJesus, Edwin; Connick, Elizabeth; Lam, Emerline G; Hecker, Emily J; Kallas, Esper G; Waters, Evan; Rhame, Frank; Sattler, Fred R; Wang, Gary P; Enrile Seedhom, Helen May; Tavares, Isabel CF; Stapleton, Jack T; Bennet, Jaclyn; Brock, James B; Scott, James; Forcht, Janet; Lama, Javier R; Valencia, Javier; Brumfield, Jennifer K; Portilla, Joaquin; Kumar, Jonathan; Navarro, Jordi; Pinto, Jorge A; Castro, Jose G; Bernardino, Jose I; Casado, Jose L; Madruga, José Valdez; Baraiaetxaburu, Josu; Berenguer, Juan; Tashima, Karen T; Ho, Ken; Costa, Laura VL; Perez Latorre, Leire; Mohapi, Lerato; López-González, L; Fantry, Lori E; Domínguez-Domínguez, Lourdes; Martín-Carbonero, Luz; Cornelissen, Lynne M; Jain, Mamta K; Masiá, Mar; Lacerda, Marcus VG; Saumoy, Maria; Villalobos-Hernández, Marina; Mall, Mark
Source
The Journal of Infectious Diseases. 222(Supplement_1)
Subject
Language
Abstract
BackgroundPatterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described.MethodsThe REPRIEVE trial (Randomized Trial to Prevent Vascular Events in HIV) enrolled persons with human immunodeficiency virus (HIV) who were aged 40-75 years, receiving ART, and had low-to-moderate cardiovascular disease risk. ART use was summarized within Global Burden of Disease (GBD) super-regions, with adjusted linear and logistic regression analyses examining associations with immune parameters and key demographics.ResultsA total of 7770 participants were enrolled, with a median age of 50 years (interquartile range, 45-55 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass index >25 (calculated as weight in kilograms divided by height in meters squared), and 49% were current or former smokers. The median CD4 T-cell count was 620/µL (interquartile range, 447-826/ µ L), and the median duration of prior ART use, 9.5 years (5.3-14.8) years. The most common ART regimens were nucleoside/nucleotide reverse-transcriptase inhibitor (NRTI) plus nonnucleoside reverse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%). Entry ART varied by GBD region, with shifts during the trial enrollment period. In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD region, sex, entry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index and smoking status.ConclusionsThere were substantial variations in ART use by geographic region and over time, likely reflecting the local availability of specific medications, changes in treatment guidelines and provider/patient preferences. The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insights regarding immune correlates and outcomes in people living with HIV.Clinical trials registrationNCT02344290.